Stocks to watch on December 10: Syngene, Brookfield REIT, Metropolis Healthcare, Tata Motors, insurance stocks, Vodafone Idea, and more

At 08:06 AM, the GIFT NIFTY futures were trading at 24,709, down 20.50 points, or 0.08%. This implies that the NIFTY50 index will open 14 points higher. 

On the global front, Chinese stocks surged, and commodities and the Australian dollar found support on Tuesday on Beijing's new promises of rate cuts and a boost to consumption, while global stocks were wobbly ahead of a crucial US inflation reading.

Australia's central bank is expected to leave its cash rate on hold at 4.35% later in the day. Overnight the S&P 500 fell 0.6%, and futures dipped 0.1% in the Asian morning.

MSCI's broadest index of Asia-Pacific shares outside Japan rose 0.3%, led by a 1% gain for the Hang Seng index and a 2% rise in the blue-chip CSI300 index.

Japan's Nikkei rose 0.4%.

In a stock exchange filing, Bharat Forge said it had approved the issue and allotment of 1.25 crore equity shares of the company to 95 eligible institutional buyers.

The issue price of the QIP has been fixed at ₹1,320 per share, which is nearly at par with the floor price.

"This represents a discount of 4.94% to the current market price (CMP) of ₹867.90 per share. The total transaction size is estimated to be ₹660 crore. The deal will be subject to a lock-in period of 60 days," the report added.

The panel approved the floor price of ₹287.55 per unit.

The unit price closed at ₹290.73 apiece on the BSE.

Last month, the company's unitholders approved a proposal to raise up to ₹3,500 crore.

"Metropolis will acquire a 100% stake in Core Diagnostics through a combination of cash and stock, financing 55% of the transaction in cash and 45% through an equity swap, totalling ₹246.8 crore. Core Diagnostics registered revenue of ₹110 crores in FY 2023-24. The equity issuance is subject to shareholder approval, and the acquisition is expected to be completed within 60 days," the press release added.

The debt-ridden telco pegged the issue price at Rs 11.28 per equity share.

LIC's equity stake in Lupin now stands at 2.542%, down from the previous 4.569%. The share sale was conducted between September 30 and December 6, according to an exchange filing.

Capacity utilisation for November 2024 at Indian Operations stood at 94%, the company said.

The growth highlights strong performance across projects, including the Mumbai-Pune Expressway and Ahmedabad-Vadodara Expressway, among others, the company said. 

"IRB attributes this growth to increased travel activity and economic momentum and is optimistic for sustained growth during the year-end season," it said.

"Effective January 2025, the price increase will vary depending on model and variant," it added.